Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation for Early-stage Non-small Cell Lung Cancer

Prospective Clinical Study of Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation for Early-stage Non-small Cell Lung Cancer

Lung cancer is the leading cause of cancer related mortality. Among them, non small cell lung cancer accounts for 85%. Only part of patients could be treated with radical surgery. Mitochondria-targeted system therapy combined with radiofrequency ablation could be an alternative treatment. Small sample clinical cases verified that this therapy could be an efficacy and safe treatment in a short period. The primary aim of this trial is to determine if the efficacy of mitochondria-targeted system therapy combined with radiofrequency ablation is comparable to that of standard surgical interventions for patients with non-small cell lung cancer.

Inclusion Criteria:

• The patient can understand and voluntarily join the study, sign the informed consent form, and the compliance is good.
• Patients with single nodule.
• Before IIB period according to the eighth edition of the TNM staging period.
• No mediastinal lymph node metastasis.
• No prior anticancer treatments including surgery, radiation,chemotherapy or local treatments.
• Eastern Cooperative Oncology Group performance status of 0 to 1
• Sufficient organ functions

Exclusion Criteria:

• Active bacterial or fungous infection.
• Simultaneous or metachronous (within the past 5 years) double cancers.
• Patients with contraindications to radiofrequency ablation and inability to complete treatment;
• Women during pregnancy or breast-feeding.
• Uncontrollable diabetes mellitus.
• Patients with severe heart, lung, kidney disease or other systemic diseases who have been judged to have a severe impact on survival or who are pre-assessed to be unable to tolerate thoracoscopic surgery